As a Barclays analyst put it, it’s been a “slow-moving car crash”. Early supply shortages pushed patients to competitors, while Novo’s cautious marketing lagged behind Lilly’s aggressive, ...

When it was riding high, Novo Nordisk could have done M&A to reduce its dependence on obesity treatments. It didn’t.

Denmark’s status as one of the few countries in Europe with an expanding economy rests in part on the success of its homegrown hero, Novo Nordisk A/S. Thanks to the pharmaceutical giant’s astronomical ...

Trade deficit data, Federal Reserve officials' remarks, earnings from Pfizer, Disney, Uber, and additional companies.